President of EIC Michiel Scheffer visits MultiplexDX
The President of the European Innovation Council (EIC), Michiel Scheffer, visited Slovakia to discuss with key partners from the public and private sectors the experience of Slovak innovators with this prestigious European program with €10 billion in funding and visit the most innovative companies already supported by EIC. Slovakia can already boast of highly innovative companies that have withstood European wide competition, such as MultiplexDX, Powerful Medical or Glycanostics, Ltd.
The key topic of the meetings with government representatives, investors and applicant companies for financing from the EIC was therefore the exchange of experience with EIC grant schemes and the identification of factors that could increase the success of Slovak companies in the program. MDX was sitting at the table as we are the first Slovak company to receive an EIC Accelerator grant for the development of a more accurate breast cancer diagnostis.
The day ended with a visit to of EIC President at MultiplexDX labs.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
